Caris Life Sciences said the company has been selected by the Hoosier Cancer Research Network and the study’s sponsor investigator, Matthew Galsky, to perform genomic tumor profiling for a new phase II bladder cancer clinical trial, HCRN GU16-257. This marks the second tumor profiling study Caris has been selected to lead within the Hoosier Cancer Research Network.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
